Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | CCR2 | P41597 | 4/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.46 |
| ▸ | MMP2 | P08253 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2492484 | 1.00 | POLB (0.53) | POLBKMT2ACYP3A4CYP2D6TP53 | |
| SCHEMBL272227 | 1.00 | POLB (0.53) | POLBKMT2ACYP3A4CYP2D6TP53 | |
| SCHEMBL14543840 | 0.79 | OPRL1 (0.66) | CYP3A4CYP2D6TP53CYP1A2TSHR | |
| SCHEMBL267764 | 0.78 | RAD52 (0.48) | CYP3A4CYP2D6TP53CYP1A2TSHR | |
| SCHEMBL8526418 | 0.78 | MMP2 (0.64) | KMT2ACYP2D6CYP1A2TSHRMMP2 | |
| SCHEMBL9275540 | 0.78 | MMP2 (0.64) | KMT2ACYP2D6CYP1A2TSHRMMP2 | |
| SCHEMBL5555507 | 0.78 | SLC1A1 (0.57) | KMT2ACYP2D6CYP1A2TSHRMMP2 | |
| SCHEMBL13151621 | 0.77 | MMP2 (0.52) | KMT2ACYP2D6MMP2 | |
| SCHEMBL16103702 | 0.77 | MMP2 (0.52) | KMT2ACYP2D6MMP2 | |
| SCHEMBL7272130 | 0.77 | SPHK1 (0.61) | POLBKMT2ADPP7MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8133864-B2 | PAR-2 agonist | KOWA COMPANY, LTD. (JP) | 2012-03-13 | — | — | US | disclosed |
| EP-1864994-B1 | PAR-2 AGONIST | KOWA CO (JP) | 2011-10-26 | — | — | EP | disclosed |
| US-20090215703-A1 | PAR-2 Agonist | KOWA COMPANY, LTD. (JP) | 2009-08-27 | — | — | US | disclosed |
| EP-1864994-A1 | PAR-2 AGONIST | Kowa Company, Ltd. (JP) | 2007-12-12 | — | — | EP | disclosed |
| EP-1864994-A1 | PAR-2 AGONIST | Kowa Company, Ltd. (JP) | 2007-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215703-A1 | PAR-2 Agonist | FPR2, F2RL1, FPR3 | POLB 4533/4885KMT2A 2045/4885CYP3A4 989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.